+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Upstaging to invasive ductal carcinoma after mastectomy for ductal carcinoma in situ: predictive factors and role of sentinel lymph node biopsy



Upstaging to invasive ductal carcinoma after mastectomy for ductal carcinoma in situ: predictive factors and role of sentinel lymph node biopsy



Breast Cancer 25(6): 663-670



The aim of this study was to investigate preoperative factors associated with ductal carcinoma in situ (DCIS) upstaged to invasive ductal carcinoma (IDC) and sentinel lymph node (SLN) status in patients who underwent mastectomy for a preoperative diagnosis of DCIS. The medical records of 220 patients who underwent mastectomy for a preoperative diagnosis of DCIS were retrospectively reviewed. Fifty-one (22.6%) of 226 lesions were upgraded to IDC after mastectomy. Preoperative factors associated with upstaging to IDC included patient-reported signs and symptoms, a clinically palpable mass, ultrasound findings classified as category 4 or 5, the ultrasound appearance of a mass or widely distributed non-mass abnormality (NMA), and a high Ki67 index. The prevalence of SLN macrometastasis was 0.9%. IDC was diagnosed for 10.9% of lesions of a preoperative ultrasound category of 0-3, 13.0% of those with no mass or NMA detected by ultrasonography, and 14.1% of lesions preoperatively diagnosed by methods other than core needle biopsy (CNB). Of those lesions, none was associated with SLN metastasis. Routinely performing SLN biopsy for patients undergoing mastectomy for a preoperative diagnosis of DCIS is overtreatment, because the prevalence of SLN metastasis was low. SLN biopsy can be omitted for most patients. In particular, we suggest omitting SLN biopsy for patients who have lesions of ultrasound category 0-3, who have neither a mass nor NMA detected by ultrasound, or whose initial diagnosis was made based on a specimen obtained by methods other than CNB.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065654619

Download citation: RISBibTeXText

PMID: 29786772

DOI: 10.1007/s12282-018-0871-7


Related references

Predictors of treatment with mastectomy, use of sentinel lymph node biopsy and upstaging to invasive cancer in patients diagnosed with breast ductal carcinoma in situ (DCIS) on core biopsy. Annals of Surgical Oncology 21(1): 66-73, 2014

Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. Journal of the American College of Surgeons 200(4): 516-526, 2005

Role of sentinel lymph node biopsy in ductal carcinoma-in-situ treated by mastectomy. Annals of Surgical Oncology 14(2): 638-645, 2006

Predictors of invasion in patients with core-needle biopsy-diagnosed ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy in ductal carcinoma in situ. Cancer 107(8): 1760-1768, 2006

Is Sentinel Lymph Node Biopsy Indicated at Completion Mastectomy for Ductal Carcinoma In Situ?. Annals of Surgical Oncology 23(7): 2229-2234, 2018

Could sentinel lymph node biopsy be exempted for ductal carcinoma in situ after mastectomy?. Breast Cancer 2018, 2018

Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion?. Annals of Surgical Oncology 7(9): 636-642, 2000

Value of sentinel lymph node biopsy in breast ductal carcinoma in situ upstaged to invasive carcinoma. Breast Journal 14(1): 55-60, 2008

Utilization of Sentinel Lymph Node Biopsy in Patients with Ductal Carcinoma In Situ Undergoing Mastectomy. Breast Diseases: A Year Book Quarterly 24(4): 372-374, 2013

Utilization of sentinel lymph node biopsy in patients with ductal carcinoma in situ undergoing mastectomy. Annals of Surgical Oncology 20(1): 24-30, 2013

Predictors of invasive breast cancer in mammographically detected microcalcification in patients with a core biopsy diagnosis of flat epithelial atypia, atypical ductal hyperplasia or ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy. Pathology, Research and Practice 208(4): 217-220, 2012

The role of sentinel lymph node biopsy in ductal carcinoma in situ. European Journal of Surgical Oncology 31(10): 1105-1111, 2005

The decision to perform or omit sentinel lymph node biopsy during mastectomy for ductal carcinoma in situ should be tailored in accordance with preoperative findings. Breast Cancer 2018, 2018

Sentinel node procedure is warranted in ductal carcinoma in situ with high risk of occult invasive carcinoma and microinvasive carcinoma treated by mastectomy. Breast Journal 14(2): 135-140, 2008

Is there a role of sentinel lymph node biopsy in ductal carcinoma in situ?: analysis of 587 cases. Breast Cancer Research and Treatment 98(3): 311-314, 2006